Drug Trial Radar · NCT07929948
A Phase Ⅱa Study of ND-003 Tablets in Patients With Idiopathic Pulmonary Fibrosis
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
10
Planned (sponsor's estimate)
Start
Aug 18, 2026
Primary completion
Jun 30, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Shenzhen NewDEL Biotech, Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung disease that predominantly affects middle-aged and older adults. Progressive replacement of normal lung parenchyma by extracellular matrix and destruction of the alveolar architecture lead to reduced lung compliance and impaired gas exchange. Clinically, IPF is characterized by progressively worsening dyspnea, restrictive ventilatory impairment, impaired gas exchange, hypoxemia, and, in advanced cases, respiratory failure. Current pharmacological treatment of IPF is primarily based on antifibrotic therapy. Pirfenidone and nintedanib were the first two antifibrotic agents approved for IPF and have been shown to slow the decline in forced vital capacity (FVC) through different mechanisms of action. Pirfenidone is an oral small-molecule agent with antifibrotic, anti-inflammatory, and antioxidant properties. Although its mechanism of action has not been fully elucidated, it is thought to involve inhibition of transforming growth factor-beta (TGF-β)-related signaling and suppression of fibroblast proliferation. Nintedanib is a multitarget tyrosine kinase inhibitor that inhibits several receptors involved in fibrotic pathways, including vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), and platelet-derived growth factor receptors (PDGFRs). More recently, nerandomilast, an oral phosphodiesterase 4B (PDE4B) inhibitor with anti-inflammatory and antifibrotic activity, has also been developed for the treatment of IPF. Despite these therapeutic advances, currently available treatments mainly slow disease progression and do not reverse established pulmonary fibrosis or cure IPF. In addition, treatment may be limited by adverse reactions and tolerability issues. Common adverse reactions associated with pirfenidone include gastrointestinal symptoms, photosensitivity reactions, and rash, while diarrhea is a frequent adverse reaction associated with nintedanib. Therefore, there remains an unmet medical need for novel therapies with improved efficacy and an acceptable safety and tolerability profile. ND-003, formerly known as ND003, is a novel small-molecule compound jointly developed by Shenzhen Xinyue Biotechnology Co., Ltd. and Shenzhen Small Molecule Innovative Drug Center Co., Ltd. for the treatment of pulmonary fibrosis. ND-003 is a kinase inhibitor targeting discoidin domain receptor 1 (DDR1), colony-stimulating factor 1 receptor (CSF1R), and platelet-derived growth factor receptor beta (PDGFR-β). By selectively interacting with these targets and modulating signaling pathways involved in fibrotic processes, ND-003 is intended to inhibit or delay the progression of tissue fibrosis. The primary objective of this study is to evaluate the preliminary efficacy of ND-003 tablets in patients with idiopathic pulmonary fibrosis and to provide scientific evidence to support dose selection for subsequent clinical development. The study will also evaluate the safety and tolerability of ND-003 tablets in patients with IPF.
Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
Interventions
ND-003 TabletsDrug
Under fasting conditions (it is recommended that participants refrain from food, but not water, for 2 hours before and 1 hour after dosing), ND-003 tablets 100mg(1 tablet) or 200 mg (2 tablets) should be administered orally once daily with warm water.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with a ≥10% decline in forced vital capacity (FVC) from baseline.Time frame: Day 1 and Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangzhou Chest Hospital
Guangzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.